Open Forum Infect Dis . Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection

[tetano]

Open Forum Infect Dis


. 2022 Jul 29;9(8)fac382.
doi: 10.1093/ofid/ofac382. eCollection 2022 Aug.
Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection


Mario A Martinez[SUP] 1 [/SUP], Ting-Yi Chen[SUP] 2 [/SUP], Hosoon Choi[SUP] 3 [/SUP], Munok Hwang[SUP] 3 [/SUP], Dhammika Navarathna[SUP] 4 [/SUP], Linhue Hao[SUP] 5 [/SUP], Michael Gale Jr[SUP] 5 [/SUP], Gregory Camus[SUP] 6 [/SUP], Hector E Ramirez[SUP] 1 [/SUP], Chetan Jinadatha[SUP] 2 [/SUP]



Affiliations

• PMID: 36039098
• PMCID: PMC9384609
• DOI: 10.1093/ofid/ofac382

Abstract

Persistent severe acute respiratory syndrome coronavirus 2 infection is difficult to treat. Here, we report a case of 5-month persistent coronavirus disease 2019 in an immunocompromised patient who was successfully treated with 30 consecutive days of remdesivir. Prolonged remdesivir infusion with concurrent cycle threshold monitoring might provide a potential solution to cure these patients with difficult-to-treat infections.

Keywords: Ct value; persistent COVID-19; prolonged remdesivir; remdesivir mutation; remdesivir resistance.